AusperBio Secures $63 Million in Series B2 Financing, Bringing 2025 Total Raised to Over $113 Million

On September 22, AusperBio, a member of the CDH family, is a clinical-stage innovative drug company focused on the research and development of proprietary targeted delivery small nucleic acid drugs with the core goal of "achieving clinical cure for chronic hepatitis B."Today, it announced the completion of a US$63 million Series B2 round of financing, with CDH VGC continuing to increase its investment.

This round of financing was led by Qiming Venture Partners in collaboration with globally renowned industry investment institutions, with participation from several top-tier investment firms in China, including DCM VGC, H&Q China Capital, OrbiMed China, Sherpa Healthcare Partners, and Vivo Capital.This is AusperBio's second round of financing successfully completed in 2025, bringing the company's total financing amount for the year to exceed 1.13 billion US dollars.

The funds raised in this round will be mainly invested in the core development areas of AusperBio, covering three major directions: First, accelerating the clinical trial process of the core product —— AHB-137, an innovative antisense oligonucleotide (ASO) drug for achieving clinical cure of chronic hepatitis B. This includes Phase III clinical trials conducted in China, Phase II clinical trials for combination therapy and treatment-naïve patients, as well as overseas Phase II clinical trials being carried out simultaneously. Second, advancing the commercialization and industrialization construction of AHB-137 ahead of time to lay the foundation for its smooth market entry and benefit hepatitis B patients globally in the future. Third, continuously expanding the company’s innovative pipeline research and development while strengthening the construction of professional teams both domestically and internationally, accumulating core technologies and talent resources for long-term corporate growth.

Dr. Guozheng Cheng, Co-founder and CEO of AusperBio, stated"We are deeply honored to once again receive the trust and support of both new and existing investors. Between 2024 and 2025, AusperBio successfully completed four rounds of financing consecutively. This not only demonstrates the capital market's strong recognition of the company’s innovative capabilities but also highlights the commercial potential of AHB-137. Standing at this significant milestone, we will fully commit ourselves to advancing the Phase III clinical trial of AHB-137 with high quality and efficiency, while continuing to accelerate the clinical development of multiple innovative oligonucleotide drugs with targeted delivery. Our goal is to address critical unmet medical needs as soon as possible."

Dr. Chengyong Yang, Co-founder and CSO of AusperBio, stated"AHB-137 can efficiently achieve the leap from obtaining the Phase I IND approval to Phase III clinical trials, which is inseparable from the firm support of investment institutions for the company's strategy. Previously, the clinical data of AHB-137 has been repeatedly published in the form of breakthrough abstracts at international academic conferences such as EASL and AASLD, drawing extensive attention and in-depth discussion from the academic community. Looking ahead, we will continue to explore more potential of AHB-137 and promote scientific breakthroughs through innovative strategies of multi-mechanism combination therapies, driving the innovation of the small nucleic acid industry with the power of science."